Michael O'Dwyer to Dexamethasone
This is a "connection" page, showing publications Michael O'Dwyer has written about Dexamethasone.
Connection Strength
0.835
-
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):847-852.
Score: 0.192
-
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 11; 22(11):1582-1596.
Score: 0.182
-
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. Blood Adv. 2019 06 25; 3(12):1815-1825.
Score: 0.155
-
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019 05 30; 380(22):2104-2115.
Score: 0.154
-
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025 Apr; 39(4):942-950.
Score: 0.058
-
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. Leukemia. 2025 Mar; 39(3):710-719.
Score: 0.057
-
The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. BMC Med Res Methodol. 2018 06 28; 18(1):66.
Score: 0.036